LDS/Medical Tests/Lung Cancer Gene Mutation Panel

Lung Cancer Gene Mutation Panel

Lung cancer is a cancer that starts in the lungs. There are two main types of lung cancer: non-small cell lung carcinoma (NSCLC), which is the most common type of lung cancer, and small cell carcinoma. Each type of non-small cell lung cancer has different kinds of cancer cells. The cancer cells of each type grow and spread in different ways. Some of the non-small cell lung cancer cells are: (i) Squamous cell carcinoma (epidermoid carcinoma), (ii) Large cell carcinoma, and (iii) Adenocarcinoma. Small cell carcinoma makes up about 20% of all lung cancer cases.

If the lung cancer is made up of both types, it is called mixed cell carcinoma. Metastatic cancers to the lungs are cancers that spread to the lungs from other parts of the body. Treatment of lung cancer can be by surgery, radiation therapy, chemotherapy, targeted therapy, laser therapy, photodynamic therapy, cryosurgery, electrocautery and watchful waiting.

Targeted therapy uses drugs or other substances to identify and attack specific cancer cells without affecting normal cells. Monoclonal antibodies and tyrosine kinase inhibitors (TKIs) are two types of targeted therapy being used in the treatment of non-small cell lung cancer.

Similar to other cancers, lung cancer is initiated by activation of oncogenes (genes believed to make people more susceptible to cancer and which are usually mutated or highly expressed) or inactivation of tumor suppressor genes. Proto-oncogenes are believed to turn into oncogenes when exposed to particular carcinogens (cancer causing substances). Identifying mutations in oncogenes associated with NSCLC can help determine how patients are more likely to benefit from a targeted therapy. Some of the oncogenes include EGFR, KRAS, ALK, BRAF, MET, p53, LKB1 and PIK3CA.

Mutations in the KRAS proto-oncogene are responsible for 10–30% of lung adenocarcinomas. Patients with KRAS mutations tend to be resistant to erlotinib and gefitinib. KRAS mutations are more likely found in adenocarcinoma. KRAS mutations are prognostic for poor survival, independent of therapy.

The epidermal growth factor receptor (EGFR) regulates cell proliferation, apoptosis (programed cell death), angiogenesis (development of new blood vessels), and tumor invasion. Activation of the EGFR protein stimulates the protein tyrosine kinase, which leads to activation of signaling pathways associated with cell growth and survival. Mutations and amplification of EGFR are common in NSCLC and provide the basis for treatment with EGFR inhibitors. The most common mutations associated with sensitivity to EGFR to tyrosine kinase inhibitors (TKIs) include exon 19 deletions and the L858R point mutation. These mutations are associated with response rates of >70% in patients treated with either erlotinib or gefitinib.

Rearrangements of the gene encoding anaplastic lymphoma kinase (ALK) have been linked to abnormal cell proliferation and NSCLC (most commonly adenocarcinomas). The most common ALK rearrangement in NSCLC is EML4-ALK, which arises from fusion between the 5′ end of the EML4 gene and the 3′ end of the ALK gene on chromosome 2p23. Patients with ALK rearrangements are younger than most patients with NSCLC.

Some labs might have extended panels including EGFR, KRAS, ALK, BRAF, MET, p53, LKB1 and PIK3CA performed by next generation sequencing. Lung cancer mutation panel is usually comprised of mutational analysis of the EGFR and KRAS genes by molecular testing and ALK locus rearrangement by FISH assay. These are the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer (NSCLC) and disease management. Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors, whereas those with evidence of ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome.

  • Differential diagnosis of lung cancer and disease management
  • Identifying mutations underlining lung cancer will serve as a rationale for choosing an appropriate and responsive targeted treatment and therapy of choice
  • Genetic mutation and gene rearrangement has prognostic and therapeutic purposes
  • Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors. Identifying EGFR mutations has been shown to predict response to erlotinib or gefitinib therapy. In general, T790M and exon 20 insertion mutations predict therapeutic resistance
  • The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome
  • KRAS mutations are predictive of lack of response to EFGR and ALK inhibitors. Different therapies should therefore be considered
  • If ALK rearrangements are detected in patients with advanced NSCLC, this would indicate eligibility for treatment with the ALK inhibitor crizotinib; however, EGFR-directed inhibitors would not be of use
  • Additional, secondary mutations may occur during therapy. These can lead to resistance to EGFR or ALK inhibitors. Examples of these mutations include the T790M mutation in EGFR and also mutations in KRAS and ALK that may go undetected
  • The expression of EGFR protein on immunohistochemistry has not been a reliable predictor of responsiveness of EGFR inhibitor

EGFR Mutation: Not detected

KRAS Mutation: Not detected

ALK, FISH: Negative for Gene Rearrangements

Polymerase chain reaction (PCR) amplification and dye-terminator sequencing, Next Generation Sequencing, Fluorescence in-situ hybridization (FISH), Immunohistochemistry, Immunoblotting and Cell culture.

Whole blood (EDTA lavender top tubes), tumor/tissue biopsy (Formalin fix, 10 percent neutral buffered formalin and paraffin embed tumor tissue) and pleural aspirates using the appropriate media.

Stability

  • Ambient: 5-7 days
  • Refrigerated: 7-14 days
  • Formalin fixed and paraffin embed tumor tissue
BRAF, MET, p53, LKB1 and PIK3CA mutation analysis, Lung biopsy, Respiratory culture, Viral culture, Acid fast bacilli (AFP) or M. tuberculosis by PCR.

7-14 days

Please log in to view content.
Create an account to get a 30-day free trial.
Login

Clinical lung cancer. 2006. 8(1): p. 30-38. [PMID: 16870043]
Proc Natl Acad Sci USA. 2007 Dec 26;104(52):20932-7 [PMID: 18093943]
J Clin Oncol. 2010 Feb 10;28(5):744-52 [PMID: 20038723]
J Natl Compr Canc Netw. 2010 Jul;8(7):740-801. [PMID: 20679538] 
Oncogene. 2009 Aug;28 Suppl 1:S24-31. [PMID: 19680293]
Cancer Res. 2006. 66(8): p. 3992-3995. [PMID: 16618717]
N Engl J Med. 2004. 350(21): p. 2129-2139. [PMID: 15118073]
Lancet Oncol. 2010. 11(2): p. 121-128. [PMID: 20022809]
J Clin Oncol. 2005 Apr 10;23(11):2556-68. [PMID: 15767641]
PLoS Med. 2005. 2(3): p. e73. [PMID: 15737014]
N Engl J Med. 2005 Jul 14;353(2):133-44. [PMID: 16014883]

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login